We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
+5.89%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+302.07%
AUM
$47.8B
AUM Growth
+$3.07B
(+6.9%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
17.74%
Holding
1,131
New
130
Increased
292
Reduced
306
Closed
143
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$526M |
| 2 |
Ally Financial
ALLY
|
+$198M |
| 3 |
CSX Corp
CSX
|
+$191M |
| 4 |
NetEase
NTES
|
+$173M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$171M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$262M |
| 2 |
CVS Health
CVS
|
+$240M |
| 3 |
Mastercard
MA
|
+$204M |
| 4 |
McKesson
MCK
|
+$201M |
| 5 |
Molson Coors Class B
TAP
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.83% |
| 2 | Communication Services | 13.94% |
| 3 | Technology | 12.15% |
| 4 | Financials | 10.5% |
| 5 | Energy | 9.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Sherwin-Williams
SHW
$85.2B
| $7.05M | 0.01% |
102,189
+5,100
| +5% | +$341K |
|
|
SIRO
402
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
| $6.95M | 0.01% |
84,324
-53,731
| -39% | -$4.09M |
|
403
Innoviva
INVA
$1.6B
| $6.74M | 0.01% |
226,445
-54,573
| -19% | -$1.31M |
|
|
JGT
404
DELISTED
NUVEEN DIVERSIFIED CURRENCY OPPORTUNIES FUND(USA)
JGT
| – | – |
0
| – | – |
|
405
Ball Corp
BALL
$17.5B
| $6.66M | 0.01% |
212,680
+15,622
| +8% | +$457K |
|
|
AVIV
406
DELISTED
AVIV REIT INC COM STK (MD)
AVIV
| $6.57M | 0.01% |
233,288
+31,957
| +16% | +$866K |
|
407
InterDigital
IDCC
$6.79B
| $6.53M | 0.01% |
136,673
-122,529
| -47% | -$4.74M |
|
408
iShares MSCI Japan Small-Cap ETF
SCJ
$248M
| $6.49M | 0.01% |
114,332
+2,695
| +2% | +$143K |
|
409
iShares US Healthcare Providers ETF
IHF
$1.23B
| $6.48M | 0.01% |
314,940
+6,650
| +2% | +$131K |
|
410
Mitsubishi UFJ Financial
MUFG
$250B
| $6.47M | 0.01% |
1,051,407
+507
| +0% | +$2.87K |
|
411
GSK
GSK
$106B
| $6.45M | 0.01% |
96,459
-240
| -0.2% | -$16.2K |
|
412
Lincoln National
LNC
$8.08B
| $6.36M | 0.01% |
123,671
-2,718
| -2% | -$134K |
|
|
BMR
413
DELISTED
BIOMED REALTY TRUST INC
BMR
| $6.26M | 0.01% |
287,030
-29,900
| -9% | -$635K |
|
|
FPO
414
DELISTED
First Potomac Realty Trust
FPO
| $6.23M | 0.01% |
475,114
| – | – |
|
|
CCG
415
DELISTED
CAMPUS CREST COMMUNITIES INC COM STK (MD)
CCG
| $6.21M | 0.01% |
717,290
| – | – |
|
416
ASE Group
ASX
$70B
| $6.2M | 0.01% |
953,759
+113,492
| +14% | +$687K |
|
417
Infosys
INFY
$50.7B
| $6.04M | 0.01% |
899,168
-123,256
| -12% | -$820K |
|
|
SCD
418
LMP Capital and Income Fund
SCD
$352M
| $6.04M | 0.01% |
340,336
-142,843
| -30% | -$2.4M |
|
419
iShares MSCI South Korea ETF
EWY
$20.2B
| $6M | 0.01% |
92,370
-107,190
| -54% | -$6.86M |
|
|
MSCC
420
DELISTED
Microsemi Corp
MSCC
| $5.88M | 0.01% |
+219,942
| New | +$5.48M |
|
421
Sanofi
SNY
$109B
| $5.87M | 0.01% |
110,435
-1,687,972
| -94% | -$89.6M |
|
|
WEB
422
DELISTED
Web.com Group, Inc.
WEB
| $5.83M | 0.01% |
202,107
-112,697
| -36% | -$3.7M |
|
|
TEN
423
DELISTED
Tenneco Inc. Class A Voting Common Stock
TEN
| $5.8M | 0.01% |
88,317
-5,761
| -6% | -$357K |
|
|
ROC
424
DELISTED
ROCKWOOD HLDGS INC
ROC
| $5.66M | 0.01% |
74,496
-5,061
| -6% | -$372K |
|
|
CLNY
425
DELISTED
Colony Capital, Inc.
CLNY
| $5.66M | 0.01% |
243,743
+45,328
| +23% | +$995K |
|
Similar funds
QCM
Lazard Asset Management's Q2 2014 Portfolio in Review
As of Q2 2014, Lazard Asset Management held 1,131 positions worth $47.8B, up 6.9% from $44.8B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Lazard Asset Management's Q2 2014 filing shows 130 new, 292 increased, 306 reduced and 143 closed positions. Its largest new stake was Ally Financial: 8,153,883 shares worth $195M. The largest sale was Gilead Sciences, an estimated $262M.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, down from 16% a quarter earlier, followed by Communication Services and Technology.
- Lazard Asset Management's largest Q2 2014 buy was Ally Financial: 8,153,883 shares worth $195M.
- Lazard Asset Management added most to Teva Pharmaceuticals in Q2 2014, an estimated $526M increase.
- Lazard Asset Management's biggest Q2 2014 reduction was Gilead Sciences, cutting an estimated $262M.
- Lazard Asset Management fully exited Mastercard in Q2 2014, selling an estimated $204M.
- Lazard Asset Management's ten largest holdings make up 18% of its $47.8B portfolio in Q2 2014.
- Lazard Asset Management opened 130 new positions and closed 143 in Q2 2014.
- Lazard Asset Management's portfolio value rose 6.9% quarter-over-quarter to $47.8B.
Based on Lazard Asset Management's 13F filing for Q2 2014, filed 12 Aug 2014.